Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13991074 | 1.00 | GABRG2 (0.34) | GABRG2GABRB3GABRA2HSP90AA1HSP90AB1 | |
| SCHEMBL8103339 | 1.00 | GABRG2 (0.34) | GABRG2GABRB3GABRA2HSP90AA1HSP90AB1 | |
| SCHEMBL4916839 | 1.00 | GABRG2 (0.34) | GABRG2GABRB3GABRA2HSP90AA1HSP90AB1 | |
| SCHEMBL2669400 | 0.90 | PIK3CA (0.35) | HSP90AA1HSP90AB1NPY1RNPY5RBRD9 | |
| SCHEMBL13991075 | 0.83 | PIK3CA (0.39) | GABRG2GABRB3GABRA2NPY1RNPY5R | |
| SCHEMBL4915461 | 0.83 | PIK3CA (0.39) | GABRG2GABRB3GABRA2NPY1RNPY5R | |
| SCHEMBL2669418 | 0.83 | PIK3CA (0.39) | GABRG2GABRB3GABRA2NPY1RNPY5R | |
| SCHEMBL4915466 | 0.83 | PIK3CA (0.39) | GABRG2GABRB3GABRA2NPY1RNPY5R | |
| SCHEMBL2669417 | 0.81 | GABRG2 (0.43) | GABRG2GABRB3GABRA2NPY1RNPY5R | |
| SCHEMBL4911805 | 0.81 | BRD9 (0.40) | GABRG2GABRB3GABRA2NPY1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.